Why this chain matters

CytomX Therapeutics, Inc. (CTMX) has a mapped ChainSifter graph with 14 supplier links and 14 customer links. That makes it useful for investors trying to understand who benefits when CTMX performs well, and who may be exposed if demand or execution weakens.

The point is not to treat every edge as equal. The useful signal is the shape of the network: named suppliers, named customers, confidence levels, and filing language that shows where business dependence may sit.

Supplier exposure

The supplier side shows the companies and entities most directly tied to CTMX's operating base. Higher-confidence links deserve the first review because they are the relationships most likely to matter when margins, production, procurement, or delivery timelines change.

  • Amgen Inc. (AMGN) - confidence 90%.
  • Bristol-Myers Squibb Company (BMY) - confidence 90%.
  • Bristol-Myers Squibb Company (BMY) - confidence 90%.
  • Amgen Inc. (AMGN) - confidence 90%.
  • MODERNA (MODERNA) - confidence 90%.
  • AbbVie Inc. (ABBV) - confidence 80%.
  • AbbVie Inc. (ABBV) - confidence 80%.
  • ASTELLAS (ASTELLAS) - confidence 80%.

Customer and demand signals

The customer side is where revenue concentration and downstream demand risk usually show up first. If a customer relationship is central to the graph, a change in that customer's spending or inventory cycle can move through the chain quickly.

  • Bristol-Myers Squibb Company (BMY) - confidence 90%.
  • Amgen Inc. (AMGN) - confidence 90%.
  • MODERNA (MODERNA) - confidence 90%.
  • Bristol-Myers Squibb Company (BMY) - confidence 90%.
  • Amgen Inc. (AMGN) - confidence 90%.
  • ASTELLAS (ASTELLAS) - confidence 80%.
  • AbbVie Inc. (ABBV) - confidence 80%.
  • AbbVie Inc. (ABBV) - confidence 80%.

Filing evidence

ChainSifter is most useful when the map is tied back to source language. These excerpts are the evidence trail behind the graph and should be reviewed before treating a relationship as investable signal.

  • CytomX Therapeutics, Inc.: In December 2022, we entered into a Collaboration and License Agreement (the "Moderna Agreement") with Moderna, pursuant to which we and Moderna will collaborate on the creation of mRNA-based conditionally-activated investigational therapies utilizing our PROB
  • CytomX Therapeutics, Inc.: In May 2014, we and Bristol Myers Squibb entered into a Collaboration and License Agreement (the "BMS Agreement") to discover and develop compounds for use in human therapeutics aimed at multiple immuno-oncology targets using our PROBODY therapeutic technology
  • MODERNA: In December 2022, we entered into a Collaboration and License Agreement (the "Moderna Agreement") with Moderna, pursuant to which we and Moderna will collaborate on the creation of mRNA-based conditionally-activated investigational therapies utilizing our PROB
  • Amgen Inc.: In September 2017, we entered into a Collaboration and License Agreement (the "Amgen Agreement") with Amgen.
  • CytomX Therapeutics, Inc.: In September 2017, we entered into a Collaboration and License Agreement (the "Amgen Agreement") with Amgen.

Who benefits and who is exposed

If CytomX Therapeutics, Inc. outperforms, the first-order beneficiaries are the suppliers with high-confidence relationships and the customers that rely on the company's output. If CTMX struggles, the exposed names are the counterparties with fewer alternate channels or relationships that appear repeatedly in the filing trail.

This is the practical use case: map the counterparties, separate confirmed relationships from weak ones, and watch for new filings that change the direction or concentration of exposure.

The most important follow-up is not simply whether a counterparty appears once. It is whether the same relationship persists across filings, appears in risk-factor language, or connects to revenue, procurement, capacity, or delivery obligations. Those are the details that turn a graph edge into investable supply chain intelligence.

How to read the signal

A compact graph can still be useful when the named counterparties are specific and the evidence is direct. Investors should read each relationship as a working hypothesis about exposure, then compare it with revenue mix, segment performance, margin pressure, and management commentary in the next filing cycle.

The strongest signals usually have three traits: a named counterparty, a clear commercial role, and repeated language over time. A one-off mention is weaker. A relationship tied to manufacturing, purchasing, licensing, distribution, or customer concentration is stronger because it can affect revenue durability, operating leverage, or execution risk.

For CytomX Therapeutics, Inc., the current graph gives analysts a starting map rather than a final conclusion. The supplier side points to operating dependencies. The customer side points to demand dependencies. The evidence trail shows which edges deserve deeper work before they are used in a trade or portfolio risk review.

What to watch

  • New or removed supplier names in future filings.
  • Customer concentration language that points to revenue dependence.
  • Confidence changes in the ChainSifter graph as new evidence is processed.